Apr 5, 2021

Featuring an interview with Dr Natalie S Callander, including the following topics:

• Treatment of high-risk smoldering multiple myeloma (MM) with carfilzomib, lenalidomide and dexamethasone followed by maintenance lenalidomide: A Phase II clinical and correlative study (0:00)
• Early versus late autologous stem cell transplant for newly diagnosed MM: Long-term follow-up analysis of the IFM 2009 trial (3:27)
• Updated analysis of the GRIFFIN trial: Daratumumab with lenalidomide, bortezomib and dexamethasone for patients with transplant-eligible newly diagnosed MM (14:48)
• Results from the ANDROMEDA trial evaluating bortezomib, cyclophosphamide and dexamethasone with or without daratumumab for newly diagnosed amyloid light chain (AL) amyloidosis (17:20)
• Interim analysis of the IKEMA trial evaluating depth of response and response kinetics with isatuximab added to carfilzomib and dexamethasone for relapsed/refractory (R/R) MM (21:23)
• KarMMa trial: Efficacy and safety of idecabtagene vicleucel in elderly patients with R/R MM (27:55)
• CARTITUDE-1: Phase Ib/II study of ciltacabtagene autoleucel, a B-cell maturation antigen-directed CAR (chimeric antigen receptor) T-cell therapy, for R/R MM (37:21)
• Activity and safety of the bispecific antibodies talquetamab and cevostamab (BFCR4350A) in patients with R/R MM (42:21)
• ANCHOR trial: Updated efficacy and safety of melflufen with either dexamethasone/daratumumab or dexamethasone/bortezomib for R/R MM (47:25)
• Iberdomide in combination with dexamethasone, daratumumab or both and with dexamethasone/bortezomib for patients with R/R MM (52:39)
• ALGONQUIN trial: Efficacy and tolerability of belantamab mafodotin with pomalidomide/dexamethasone for patients with R/R MM (55:33)
• Selinexor in combination with pomalidomide and dexamethasone for R/R MM (57:29)
• Phase II SWOG-S1702 study of isatuximab for patients with previously treated AL amyloidosis (1:00:17)
• Safety and efficacy of CAEL-101 in patients with AL amyloidosis on a Phase II dose selection study (1:02:02)
• Five-year follow-up of ibrutinib with rituximab for Waldenström macroglobulinemia (WM): Final analysis from the Phase III iNNOVATE^TM study (1:04:06)
• Bortezomib in combination with dexamethasone, rituximab and cyclophosphamide as first-line treatment for WM: Results of a randomized Phase II trial (1:07:11)
• Roles of zanubrutinib and acalabrutinib for WM (1:09:40)

CME information and select publications